The global carrier screening market was valued at $1,849.36 million in 2021 and is projected to reach $6,454.60 million by 2031, registering a CAGR of 13.8% from 2022 to 2031. Genetic testing is done for checking if people have genetic conditions or diseases that may be present in the family history prior to the occurrence of the symptoms or if people can pass on that genetic condition to their children. Genetic counselors help people decide what tests to get and understand the meaning of tests. It can be done on amniotic fluid through amniocentesis or the placenta through chorionic villus sampling in pregnant women. It can also be done on an embryo during in vitro fertilization (IVF). Usually, it takes a few weeks for test results to be ready. Some of the diseases for which genetic testing is preferred include cystic fibrosis, Tay-Sachs disease, sickle cell disease, down syndrome, spina bifida, turner syndrome, von Willebrand disease, albinism, and Duchenne muscular dystrophy.
An increase in the incidence of genetic diseases, a rise in the number of advanced product launches, and a surge in the availability & affordability of tests are the factors responsible for driving the growth of the market. Moreover, an increase in the number of biotechnology companies adopting strategies like acquisition is expected to notably contribute toward market growth. For instance, in August 2021, DiaSorin S.p.A. announced that it has completed the acquisition of Luminex Corporation for a price of $37.00 per share which corresponds to a total equity value of approximately $1.8 billion. Through the acquisition, DiaSorin has gained access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the U.S. In addition, the global carrier screening market growth is largely driven by factors such as an increase in preference of carrier screening in genetic disorder fields, various initiatives & funding from government & private bodies for large-scale carrier screening projects and decline in cost of screening. The key market players in the global carrier screening market have opted for various strategies such as investments in R&D for advancement in carrier screening to strengthen their position in the market and sustain the competitive environment. However, the high cost associated with carrier screening and the dearth of skilled professionals restricts the market growth. Conversely, various technological advancements such as the development of next-generation sequencing (NGS) techniques for genetic disease screening and DNA sequencing are expected to provide lucrative opportunities for the growth of the market in the coming years. The increase in the R&D activities in the field of bioinformatics and biotechnology along with significant improvement in medical infrastructure is anticipated to increase the opportunities of the market.
The carrier screening market is segmented based on type, technology, end-user, and region. On the basis of type, the market is bifurcated into expanded carrier screening and targeted disease carrier screening. On the basis of technology, the market is classified into DNA sequencing, polymerase chain reaction, microarrays, and others. On the basis of end users, the market is classified into hospitals & clinics, reference laboratories, physician offices, and others. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Diasorin S.p. A (Luminex Corporation), Eurofins Scientific, Fulgent Genetics Inc., Illumina Inc., Invitae Corporation, Myriad Genetics Inc., Natera Inc., Opko Health Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the carrier screening market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes analysis of the regional as well as global carrier screening market trends, key players, market segments, application areas, and market growth strategies.
An increase in the incidence of genetic diseases, a rise in the number of advanced product launches, and a surge in the availability & affordability of tests are the factors responsible for driving the growth of the market. Moreover, an increase in the number of biotechnology companies adopting strategies like acquisition is expected to notably contribute toward market growth. For instance, in August 2021, DiaSorin S.p.A. announced that it has completed the acquisition of Luminex Corporation for a price of $37.00 per share which corresponds to a total equity value of approximately $1.8 billion. Through the acquisition, DiaSorin has gained access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the U.S. In addition, the global carrier screening market growth is largely driven by factors such as an increase in preference of carrier screening in genetic disorder fields, various initiatives & funding from government & private bodies for large-scale carrier screening projects and decline in cost of screening. The key market players in the global carrier screening market have opted for various strategies such as investments in R&D for advancement in carrier screening to strengthen their position in the market and sustain the competitive environment. However, the high cost associated with carrier screening and the dearth of skilled professionals restricts the market growth. Conversely, various technological advancements such as the development of next-generation sequencing (NGS) techniques for genetic disease screening and DNA sequencing are expected to provide lucrative opportunities for the growth of the market in the coming years. The increase in the R&D activities in the field of bioinformatics and biotechnology along with significant improvement in medical infrastructure is anticipated to increase the opportunities of the market.
The carrier screening market is segmented based on type, technology, end-user, and region. On the basis of type, the market is bifurcated into expanded carrier screening and targeted disease carrier screening. On the basis of technology, the market is classified into DNA sequencing, polymerase chain reaction, microarrays, and others. On the basis of end users, the market is classified into hospitals & clinics, reference laboratories, physician offices, and others. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Diasorin S.p. A (Luminex Corporation), Eurofins Scientific, Fulgent Genetics Inc., Illumina Inc., Invitae Corporation, Myriad Genetics Inc., Natera Inc., Opko Health Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the carrier screening market analysis from 2021 to 2031 to identify the prevailing carrier screening market opportunities.Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the carrier screening market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes analysis of the regional as well as global carrier screening market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Expanded Carrier Screening
- Targeted Disease Carrier Screening
By Technology
- DNA Sequencing
- Polymerase Chain Reaction
- Microarrays
- Others
By End User
- Hospitals and clinics
- Reference Laboratories
- Physician Offices
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Fulgent Genetics Inc.
- Illumina Inc.
- Diasorin S.p.A.
- Natera Inc.
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Myriad Genetics, Inc.
- Opko Health Inc
- Quest Diagnostics Inc.
- InVitae Corporation
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the prevalence of genetic disorders
3.4.1.2. Rise in the technological advancements
3.4.1.3. Rise in awareness for early disease diagnosis
3.4.2. Restraints
3.4.2.1. High cost associated with carrier screening and dearth of skilled professionals
3.4.3. Opportunities
3.4.3.1. Rise in the number of R&D investment by pharmaceutical companies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CARRIER SCREENING MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2. Expanded Carrier Screening
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Targeted Disease Carrier Screening
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: CARRIER SCREENING MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2. DNA Sequencing
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. Polymerase Chain Reaction
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4. Microarrays
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
5.5. Others
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market share analysis by country
CHAPTER 6: CARRIER SCREENING MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2. Hospitals and clinics
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3. Reference Laboratories
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4. Physician Offices
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
6.5. Others
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market share analysis by country
CHAPTER 7: CARRIER SCREENING MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Technology
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Technology
7.2.5.1.4 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Technology
7.2.5.2.4 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Technology
7.2.5.3.4 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Technology
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Technology
7.3.5.1.4 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Technology
7.3.5.2.4 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Technology
7.3.5.3.4 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Technology
7.3.5.4.4 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Technology
7.3.5.5.4 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Technology
7.3.5.6.4 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Technology
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Technology
7.4.5.1.4 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Technology
7.4.5.2.4 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Technology
7.4.5.3.4 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Technology
7.4.5.4.4 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Technology
7.4.5.5.4 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Technology
7.4.5.6.4 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Technology
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Technology
7.5.5.1.4 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Technology
7.5.5.2.4 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Technology
7.5.5.3.4 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Technology
7.5.5.4.4 Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1 Fulgent Genetics Inc.
9.1.1 Company overview
9.1.2 Key Executives
9.1.3 Company snapshot
9.1.4 Operating business segments
9.1.5 Product portfolio
9.1.6 Business performance
9.1.7 Key strategic moves and developments
9.2 Illumina Inc.
9.2.1 Company overview
9.2.2 Key Executives
9.2.3 Company snapshot
9.2.4 Operating business segments
9.2.5 Product portfolio
9.2.6 Business performance
9.2.7 Key strategic moves and developments
9.3 Diasorin S.p.A.
9.3.1 Company overview
9.3.2 Key Executives
9.3.3 Company snapshot
9.3.4 Operating business segments
9.3.5 Product portfolio
9.3.6 Business performance
9.3.7 Key strategic moves and developments
9.4 Natera Inc.
9.4.1 Company overview
9.4.2 Key Executives
9.4.3 Company snapshot
9.4.4 Operating business segments
9.4.5 Product portfolio
9.4.6 Business performance
9.4.7 Key strategic moves and developments
9.5 Thermo Fisher Scientific Inc.
9.5.1 Company overview
9.5.2 Key Executives
9.5.3 Company snapshot
9.5.4 Operating business segments
9.5.5 Product portfolio
9.5.6 Business performance
9.5.7 Key strategic moves and developments
9.6 Eurofins Scientific
9.6.1 Company overview
9.6.2 Key Executives
9.6.3 Company snapshot
9.6.4 Operating business segments
9.6.5 Product portfolio
9.6.6 Business performance
9.6.7 Key strategic moves and developments
9.7 Myriad Genetics, Inc.
9.7.1 Company overview
9.7.2 Key Executives
9.7.3 Company snapshot
9.7.4 Operating business segments
9.7.5 Product portfolio
9.7.6 Business performance
9.7.7 Key strategic moves and developments
9.8 Opko Health Inc
9.8.1 Company overview
9.8.2 Key Executives
9.8.3 Company snapshot
9.8.4 Operating business segments
9.8.5 Product portfolio
9.8.6 Business performance
9.8.7 Key strategic moves and developments
9.9 Quest Diagnostics Inc.
9.9.1 Company overview
9.9.2 Key Executives
9.9.3 Company snapshot
9.9.4 Operating business segments
9.9.5 Product portfolio
9.9.6 Business performance
9.9.7 Key strategic moves and developments
9.10 InVitae Corporation
9.10.1 Company overview
9.10.2 Key Executives
9.10.3 Company snapshot
9.10.4 Operating business segments
9.10.5 Product portfolio
9.10.6 Business performance
9.10.7 Key strategic moves and developments
List of Tables
Table 1. Global Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 2. Carrier Screening Market for Expanded Carrier Screening, by Region, 2021-2031 (Revenue, $Million)
Table 3. Carrier Screening Market for Targeted Disease Carrier Screening, by Region, 2021-2031 (Revenue, $Million)
Table 4. Global Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 5. Carrier Screening Market for Dna Sequencing, by Region, 2021-2031 (Revenue, $Million)
Table 6. Carrier Screening Market for Polymerase Chain Reaction, by Region, 2021-2031 (Revenue, $Million)
Table 7. Carrier Screening Market for Microarrays, by Region, 2021-2031 (Revenue, $Million)
Table 8. Carrier Screening Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 9. Global Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 10. Carrier Screening Market for Hospitals and Clinics, by Region, 2021-2031 (Revenue, $Million)
Table 11. Carrier Screening Market for Reference Laboratories, by Region, 2021-2031 (Revenue, $Million)
Table 12. Carrier Screening Market for Physician Offices, by Region, 2021-2031 (Revenue, $Million)
Table 13. Carrier Screening Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 14. Carrier Screening Market, by Region, 2021-2031 (Revenue, $Million)
Table 15. North America Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 16. North America Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 17. North America Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 18. North America Carrier Screening Market, by Country, 2021-2031 (Revenue, $Million)
Table 19. U.S. Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 20. U.S. Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 21. U.S. Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 22. Canada Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 23. Canada Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 24. Canada Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 25. Mexico Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 26. Mexico Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 27. Mexico Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 28. Europe Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 29. Europe Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 30. Europe Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 31. Europe Carrier Screening Market, by Country, 2021-2031 (Revenue, $Million)
Table 32. Germany Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 33. Germany Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 34. Germany Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 35. France Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 36. France Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 37. France Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 38. UK Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 39. UK Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 40. UK Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 41. Italy Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 42. Italy Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 43. Italy Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 44. Spain Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 45. Spain Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 46. Spain Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 48. Rest of Europe Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 49. Rest of Europe Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 52. Asia-Pacific Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 53. Asia-Pacific Carrier Screening Market, by Country, 2021-2031 (Revenue, $Million)
Table 54. Japan Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 55. Japan Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 56. Japan Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 57. China Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 58. China Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 59. China Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 60. Australia Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 61. Australia Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 62. Australia Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 63. India Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 64. India Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 65. India Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 66. South Korea Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 67. South Korea Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 68. South Korea Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 69. Rest of Asia-Pacific Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 70. Rest of Asia-Pacific Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 71. Rest of Asia-Pacific Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 72. LAMEA Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 73. LAMEA Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 74. LAMEA Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 75. LAMEA Carrier Screening Market, by Country, 2021-2031 (Revenue, $Million)
Table 76. Brazil Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 77. Brazil Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 78. Brazil Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 79. Saudi Arabia Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 80. Saudi Arabia Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 81. Saudi Arabia Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 82. South Africa Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 83. South Africa Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 84. South Africa Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 85. Rest of LAMEA Carrier Screening Market, by Type, 2021-2031 (Revenue, $Million)
Table 86. Rest of LAMEA Carrier Screening Market, by Technology, 2021-2031 (Revenue, $Million)
Table 87. Rest of LAMEA Carrier Screening Market, by End-user, 2021-2031 (Revenue, $Million)
Table 88. Fulgent Genetics Inc.: Key Executives
Table 89. Fulgent Genetics Inc.: Company Snapshot
Table 90. Fulgent Genetics Inc.: Operating Segments
Table 91. Fulgent Genetics Inc.: Product Portfolio
Table 92. Fulgent Genetics Inc.: Net Sales
Table 93. Fulgent Genetics Inc.: Key Stratergies
Table 94. Illumina Inc.: Key Executives
Table 95. Illumina Inc.: Company Snapshot
Table 96. Illumina Inc.: Operating Segments
Table 97. Illumina Inc.: Product Portfolio
Table 98. Illumina Inc.: Net Sales
Table 99. Illumina Inc.: Key Stratergies
Table 100. Diasorin S.P.A.: Key Executives
Table 101. Diasorin S.P.A.: Company Snapshot
Table 102. Diasorin S.P.A.: Operating Segments
Table 103. Diasorin S.P.A.: Product Portfolio
Table 104. Diasorin S.P.A.: Net Sales
Table 105. Diasorin S.P.A.: Key Stratergies
Table 106. Natera Inc.: Key Executives
Table 107. Natera Inc.: Company Snapshot
Table 108. Natera Inc.: Operating Segments
Table 109. Natera Inc.: Product Portfolio
Table 110. Natera Inc.: Net Sales
Table 111. Natera Inc.: Key Stratergies
Table 112. Thermo Fisher Scientific Inc.: Key Executives
Table 113. Thermo Fisher Scientific Inc.: Company Snapshot
Table 114. Thermo Fisher Scientific Inc.: Operating Segments
Table 115. Thermo Fisher Scientific Inc.: Product Portfolio
Table 116. Thermo Fisher Scientific Inc.: Net Sales
Table 117. Thermo Fisher Scientific Inc.: Key Stratergies
Table 118. Eurofins Scientific: Key Executives
Table 119. Eurofins Scientific: Company Snapshot
Table 120. Eurofins Scientific: Operating Segments
Table 121. Eurofins Scientific: Product Portfolio
Table 122. Eurofins Scientific: Net Sales
Table 123. Eurofins Scientific: Key Stratergies
Table 124. Myriad Genetics, Inc.: Key Executives
Table 125. Myriad Genetics, Inc.: Company Snapshot
Table 126. Myriad Genetics, Inc.: Operating Segments
Table 127. Myriad Genetics, Inc.: Product Portfolio
Table 128. Myriad Genetics, Inc.: Net Sales
Table 129. Myriad Genetics, Inc.: Key Stratergies
Table 130. Opko Health Inc: Key Executives
Table 131. Opko Health Inc: Company Snapshot
Table 132. Opko Health Inc: Operating Segments
Table 133. Opko Health Inc: Product Portfolio
Table 134. Opko Health Inc: Net Sales
Table 135. Opko Health Inc: Key Stratergies
Table 136. Quest Diagnostics Inc.: Key Executives
Table 137. Quest Diagnostics Inc.: Company Snapshot
Table 138. Quest Diagnostics Inc.: Operating Segments
Table 139. Quest Diagnostics Inc.: Product Portfolio
Table 140. Quest Diagnostics Inc.: Net Sales
Table 141. Quest Diagnostics Inc.: Key Stratergies
Table 142. Invitae Corporation: Key Executives
Table 143. Invitae Corporation: Company Snapshot
Table 144. Invitae Corporation: Operating Segments
Table 145. Invitae Corporation: Product Portfolio
Table 146. Invitae Corporation: Net Sales
Table 147. Invitae Corporation: Key Stratergies
List of Figures
Figure 1. Segmentation of Carrier Screening Market, 2021-2031
Figure 2. Carrier Screening Market, 2021-2031
Figure 3. Top Investment Pockets, by Region
Figure 4. Porter Five-1
Figure 5. Porter Five-2
Figure 6. Porter Five-3
Figure 7. Porter Five-4
Figure 8. Porter Five-5
Figure 9. Carrier Screening Market: Drivers, Restraints and Opportunities
Figure 10. Carrier Screening Market, by Type, 2021 (%)
Figure 11. Comparative Share Analysis of Expanded Carrier Screening Carrier Screening Market, 2021 and 2031 (%)
Figure 12. Comparative Share Analysis of Targeted Disease Carrier Screening Carrier Screening Market, 2021 and 2031 (%)
Figure 13. Carrier Screening Market, by Technology, 2021 (%)
Figure 14. Comparative Share Analysis of Dna Sequencing Carrier Screening Market, 2021 and 2031 (%)
Figure 15. Comparative Share Analysis of Polymerase Chain Reaction Carrier Screening Market, 2021 and 2031 (%)
Figure 16. Comparative Share Analysis of Microarrays Carrier Screening Market, 2021 and 2031 (%)
Figure 17. Comparative Share Analysis of Others Carrier Screening Market, 2021 and 2031 (%)
Figure 18. Carrier Screening Market, by End-user, 2021 (%)
Figure 19. Comparative Share Analysis of Hospitals and Clinics Carrier Screening Market, 2021 and 2031 (%)
Figure 20. Comparative Share Analysis of Reference Laboratories Carrier Screening Market, 2021 and 2031 (%)
Figure 21. Comparative Share Analysis of Physician Offices Carrier Screening Market, 2021 and 2031 (%)
Figure 22. Comparative Share Analysis of Others Carrier Screening Market, 2021 and 2031 (%)
Figure 23. Carrier Screening Market by Region, 2021
Figure 24. U.S. Carrier Screening Market, 2021-2031 ($Million)
Figure 25. Canada Carrier Screening Market, 2021-2031 ($Million)
Figure 26. Mexico Carrier Screening Market, 2021-2031 ($Million)
Figure 27. Germany Carrier Screening Market, 2021-2031 ($Million)
Figure 28. France Carrier Screening Market, 2021-2031 ($Million)
Figure 29. UK Carrier Screening Market, 2021-2031 ($Million)
Figure 30. Italy Carrier Screening Market, 2021-2031 ($Million)
Figure 31. Spain Carrier Screening Market, 2021-2031 ($Million)
Figure 32. Rest of Europe Carrier Screening Market, 2021-2031 ($Million)
Figure 33. Japan Carrier Screening Market, 2021-2031 ($Million)
Figure 34. China Carrier Screening Market, 2021-2031 ($Million)
Figure 35. Australia Carrier Screening Market, 2021-2031 ($Million)
Figure 36. India Carrier Screening Market, 2021-2031 ($Million)
Figure 37. South Korea Carrier Screening Market, 2021-2031 ($Million)
Figure 38. Rest of Asia-Pacific Carrier Screening Market, 2021-2031 ($Million)
Figure 39. Brazil Carrier Screening Market, 2021-2031 ($Million)
Figure 40. Saudi Arabia Carrier Screening Market, 2021-2031 ($Million)
Figure 41. South Africa Carrier Screening Market, 2021-2031 ($Million)
Figure 42. Rest of LAMEA Carrier Screening Market, 2021-2031 ($Million)
Figure 43. Top Winning Strategies, by Year
Figure 44. Top Winning Strategies, by Development
Figure 45. Top Winning Strategies, by Company
Figure 46. Product Mapping of Top 10 Players
Figure 47. Competitive Dashboard
Figure 48. Competitive Heatmap of Top 10 Key Players
Figure 49. Top Player Positioning, 2021
Figure 50. Fulgent Genetics Inc..: Net Sales ($Million)
Figure 51. Illumina Inc..: Net Sales ($Million)
Figure 52. Diasorin S.P.A..: Net Sales ($Million)
Figure 53. Natera Inc..: Net Sales ($Million)
Figure 54. Thermo Fisher Scientific Inc..: Net Sales ($Million)
Figure 55. Eurofins Scientific.: Net Sales ($Million)
Figure 56. Myriad Genetics, Inc..: Net Sales ($Million)
Figure 57. Opko Health Inc.: Net Sales ($Million)
Figure 58. Quest Diagnostics Inc..: Net Sales ($Million)
Figure 59. Invitae Corporation.: Net Sales ($Million)
Executive Summary
According to the report titled, “Carrier Screening Market," The carrier screening market was valued at $1.9 billion in 2021, and is estimated to reach $6.5 billion by 2031, growing at a CAGR of 13.8% from 2022 to 2031.Genetic testing is done for checking if people have genetic conditions or diseases that may be present in the family history prior to the occurrence of the symptoms or if people can pass on that genetic condition to their children. Genetic counselors help people decide what tests to get and understand the meaning of tests. It can be done on amniotic fluid through amniocentesis or the placenta through chorionic villus sampling in pregnant women. It can also be done on an embryo during in vitro fertilization (IVF). Usually, it takes a few weeks for test results to be ready. Some of the diseases for which genetic testing is preferred include cystic fibrosis, Tay-Sachs disease, sickle cell disease, down syndrome, spina bifida, turner syndrome, von Willebrand disease, albinism, and Duchenne muscular dystrophy.
An increase in the incidence of genetic diseases, a rise in the number of advanced product launches, and a surge in the availability & affordability of tests are the factors responsible for driving the growth of the market. Moreover, an increase in the number of biotechnology companies adopting strategies like acquisition is expected to notably contribute toward market growth. For instance, in August 2021, DiaSorin S.p.A. announced that it has completed the acquisition of Luminex Corporation for a price of $37.00 per share which corresponds to a total equity value of approximately $1.8 billion. Through the acquisition, DiaSorin has gained access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the U.S. In addition, the global carrier screening market growth is largely driven by factors such as an increase in preference of carrier screening in genetic disorder fields, various initiatives & funding from government & private bodies for large-scale carrier screening projects and decline in cost of screening. The key market players in the global carrier screening market have opted for various strategies such as investments in R&D for advancement in carrier screening to strengthen their position in the market and sustain the competitive environment. However, the high cost associated with carrier screening and the dearth of skilled professionals restricts the market growth. Conversely, various technological advancements such as the development of next-generation sequencing (NGS) techniques for genetic disease screening and DNA sequencing are expected to provide lucrative opportunities for the growth of the market in the coming years. The increase in the R&D activities in the field of bioinformatics and biotechnology along with significant improvement in medical infrastructure is anticipated to increase the opportunities of the market.
The carrier screening market is segmented based on type, technology, end-user, and region. On the basis of type, the market is bifurcated into expanded carrier screening and targeted disease carrier screening. On the basis of technology, the market is classified into DNA sequencing, polymerase chain reaction, microarrays, and others. On the basis of end users, the market is classified into hospitals & clinics, reference laboratories, physician offices, and others. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Diasorin S.p. A (Luminex Corporation), Eurofins Scientific, Fulgent Genetics Inc., Illumina Inc., Invitae Corporation, Myriad Genetics Inc., Natera Inc., Opko Health Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2022 to 2031, which assists to identify the prevailing market opportunities.An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the carrier screening market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Companies Mentioned
- Fulgent Genetics Inc.
- Illumina Inc.
- Diasorin S.p.A.
- Natera Inc.
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Myriad Genetics, Inc.
- Opko Health Inc
- Quest Diagnostics Inc.
- InVitae Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 350 |
| Published | December 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1849.36 million |
| Forecasted Market Value ( USD | $ 6454.6 million |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
